bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Authors: Slingluff Craig L. , Petroni Gina R. , Molhoek Kerrington R. , Brautigan David L. , Chianese-Bullock Kimberly A. , Shada Amber L. , Smolkin Mark E. , Olson Walter C. , Gaucher Alison , Chase Cheryl Murphy , Grosh William W. , Weiss Geoffrey R. , Wagenseller Aubrey G. , Olszanski Anthony J. , Martin Lainie , Shea Sofia M. , Erdag Gulsun , Ram Prahlad , Gershenwald Jeffrey E. , Weber Michael J.
Published: April 2023

PDF file - 39K, Lymphocyte counts for all patients on study - detail.
SWEAVE Data from A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Authors: Tang Hao , Xiao Guanghua , Behrens Carmen , Schiller Joan , Allen Jeffrey , Chow Chi-Wan , Suraokar Milind , Corvalan Alejandro , Mao Jianhua , White Michael A. , Wistuba Ignacio I. , Minna John D. , Xie Yang
Published: April 2023

PDF file - 124K, The SWEAVE report contains all the details about the model, parameters and procedures used to generate the results in the paper.
Data Supplement from T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Authors: Pinto Filipe , Pértega-Gomes Nelma , Pereira Márcia S. , Vizcaíno José R. , Monteiro Pedro , Henrique Rui M. , Baltazar Fátima , Andrade Raquel P. , Reis Rui M.
Published: April 2023

Supplementary Table and Figure Legends.
Table S2 from Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Authors: Van Looy Thomas , Wozniak Agnieszka , Floris Giuseppe , Sciot Raf , Li Haifu , Wellens Jasmien , Vanleeuw Ulla , Fletcher Jonathan A. , Manley Paul W. , Debiec-Rychter Maria , Schöffski Patrick
Published: April 2023

Table S2. Comparison in tumour volumes, proliferative and apoptotic activity between two weeks (end of treatment) and 5 weeks (end of regrowth experiment).
Data Supplement from T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Authors: Pinto Filipe , Pértega-Gomes Nelma , Pereira Márcia S. , Vizcaíno José R. , Monteiro Pedro , Henrique Rui M. , Baltazar Fátima , Andrade Raquel P. , Reis Rui M.
Published: April 2023

Supplementary Table S2. Correlation between Brachyury expression and molecular markers.
Figure S2 from Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Authors: Van Looy Thomas , Wozniak Agnieszka , Floris Giuseppe , Sciot Raf , Li Haifu , Wellens Jasmien , Vanleeuw Ulla , Fletcher Jonathan A. , Manley Paul W. , Debiec-Rychter Maria , Schöffski Patrick
Published: April 2023

Figure S2. The assessment of the effect of PI3K inhibitors and their combination with IMA on KIT signalling in UZLX-GIST3 (A), UZLX-GIST4 (B), UZLX-GIST2 (C) and GIST48 (D) tumours. Tumours specimens were snap-frozen at week two, upon treatment discontinuation.
Figure S1 from Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Authors: Van Looy Thomas , Wozniak Agnieszka , Floris Giuseppe , Sciot Raf , Li Haifu , Wellens Jasmien , Vanleeuw Ulla , Fletcher Jonathan A. , Manley Paul W. , Debiec-Rychter Maria , Schöffski Patrick
Published: April 2023

Figure S1. Xenograft tumour volume assessment for the efficacy experiment. Tumour volume is displayed as percentage and normalized for baseline values and presented for UZLX-GIST3 (A), UZLX-GIST4 (B), UZLX-GIST2 (C), and GIST48 (D).
Data Supplement from T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Authors: Pinto Filipe , Pértega-Gomes Nelma , Pereira Márcia S. , Vizcaíno José R. , Monteiro Pedro , Henrique Rui M. , Baltazar Fátima , Andrade Raquel P. , Reis Rui M.
Published: April 2023

Supplementary Figure S3. Brachyury characterization and modulation in prostate cancer cell lines.
Data Supplement from T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Authors: Pinto Filipe , Pértega-Gomes Nelma , Pereira Márcia S. , Vizcaíno José R. , Monteiro Pedro , Henrique Rui M. , Baltazar Fátima , Andrade Raquel P. , Reis Rui M.
Published: April 2023

Supplementary Figure S5. Brachyury overexpression modulates expression of EMT and stem cell markers in prostate cancer cell lines.
Supplementary Figure 9 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Authors: Liu Chengwen , Peng Weiyi , Xu Chunyu , Lou Yanyan , Zhang Minying , Wargo Jennifer A. , Chen Jie Qing , Li Haiyan S. , Watowich Stephanie S. , Yang Yan , Frederick Dennie Tompers , Cooper Zachary A. , Mbofung Rina M. , Whittington Mayra , Flaherty Keith T. , Woodman Scott E. , Davies Michael A. , Radvanyi Laszlo G. , Overwijk Willem W. , Lizée Gregory , Hwu Patrick
Published: April 2023

PDF file - 52K, PLX4720 exposure reduces binding of c-myc to the VEGF promoter in BRAF mutant melanoma cells
Data Supplement from Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Authors: Suryani Santi , Carol Hernan , Chonghaile Triona Ni , Frismantas Viktoras , Sarmah Chintanu , High Laura , Bornhauser Beat , Cowley Mark J. , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Tonna Elise , Jones Luke , Manesh Donya Moradi , Kurmasheva Raushan T. , Billups Catherine , Kaplan Warren , Letai Anthony , Bourquin Jean-Pierre , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

Supplementary Tables S1-S4. Summary of the Objective Response Measure (ORM) scoring method; S2. Details of known chromosomal translocations in the xenograft panel; S3. Top 100 discriminating genes for each xenograft subtype identified by microarray analysis of gene expression; S4. Gene Set Enrichment Analysis (GSEA) of subtype specific genes
Data Supplement from Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Authors: Suryani Santi , Carol Hernan , Chonghaile Triona Ni , Frismantas Viktoras , Sarmah Chintanu , High Laura , Bornhauser Beat , Cowley Mark J. , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Tonna Elise , Jones Luke , Manesh Donya Moradi , Kurmasheva Raushan T. , Billups Catherine , Kaplan Warren , Letai Anthony , Bourquin Jean-Pierre , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

Supplementary Tables S5-S8. Complete summary of in vivo single-agent ABT-263 responses of individual mice; S7. In vivo efficacy of combining ABT-263 with vincristine (VCR), dexamethasone (DEX) or L-asparaginase (L-ASN) against pediatric ALL Xenografts; S8. Complete summary of in vivo responses of ABT-263 combined with vincristine (VCR), dexamethasone (DEX) or L-asparaginase (L-ASN) of individual mice
Supplementary Figure 4 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Authors: Liu Chengwen , Peng Weiyi , Xu Chunyu , Lou Yanyan , Zhang Minying , Wargo Jennifer A. , Chen Jie Qing , Li Haiyan S. , Watowich Stephanie S. , Yang Yan , Frederick Dennie Tompers , Cooper Zachary A. , Mbofung Rina M. , Whittington Mayra , Flaherty Keith T. , Woodman Scott E. , Davies Michael A. , Radvanyi Laszlo G. , Overwijk Willem W. , Lizée Gregory , Hwu Patrick
Published: April 2023

PDF file - 24K, Pmel-1 T cells in the peripheral blood of tumor-bearing mice
Supplementary Figure 3 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Authors: Liu Chengwen , Peng Weiyi , Xu Chunyu , Lou Yanyan , Zhang Minying , Wargo Jennifer A. , Chen Jie Qing , Li Haiyan S. , Watowich Stephanie S. , Yang Yan , Frederick Dennie Tompers , Cooper Zachary A. , Mbofung Rina M. , Whittington Mayra , Flaherty Keith T. , Woodman Scott E. , Davies Michael A. , Radvanyi Laszlo G. , Overwijk Willem W. , Lizée Gregory , Hwu Patrick
Published: April 2023

PDF file - 491K, Administration of PLX4720 in vivo increases tumor infiltration of adoptively transferred T cells
Data Supplement from Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Authors: Suryani Santi , Carol Hernan , Chonghaile Triona Ni , Frismantas Viktoras , Sarmah Chintanu , High Laura , Bornhauser Beat , Cowley Mark J. , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Tonna Elise , Jones Luke , Manesh Donya Moradi , Kurmasheva Raushan T. , Billups Catherine , Kaplan Warren , Letai Anthony , Bourquin Jean-Pierre , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

Supplementary Methods for Suryani Carol et al
Supplementary Figure 11 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Authors: Liu Chengwen , Peng Weiyi , Xu Chunyu , Lou Yanyan , Zhang Minying , Wargo Jennifer A. , Chen Jie Qing , Li Haiyan S. , Watowich Stephanie S. , Yang Yan , Frederick Dennie Tompers , Cooper Zachary A. , Mbofung Rina M. , Whittington Mayra , Flaherty Keith T. , Woodman Scott E. , Davies Michael A. , Radvanyi Laszlo G. , Overwijk Willem W. , Lizée Gregory , Hwu Patrick
Published: April 2023

PDF file - 38K, mRNA levels of VEGF in patients with metastatic melanoma undergoing treatment with a selective inhibitor of BRAF(V600E)
Supplementary Figure 10 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Authors: Liu Chengwen , Peng Weiyi , Xu Chunyu , Lou Yanyan , Zhang Minying , Wargo Jennifer A. , Chen Jie Qing , Li Haiyan S. , Watowich Stephanie S. , Yang Yan , Frederick Dennie Tompers , Cooper Zachary A. , Mbofung Rina M. , Whittington Mayra , Flaherty Keith T. , Woodman Scott E. , Davies Michael A. , Radvanyi Laszlo G. , Overwijk Willem W. , Lizée Gregory , Hwu Patrick
Published: April 2023

PDF file - 27K, Growth inhibition of human melanoma cell lines
Data Supplement from Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer
Authors: Amendt Christiane , Staub Eike , Friese-Hamim Manja , Störkel Stephan , Stroh Christopher
Published: April 2023

Table S1. Non-small cell lung cancer xenograft models.
Supplementary Figure 3 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
Authors: Aarntzen Erik H. J. G. , Schreibelt Gerty , Bol Kalijn , Lesterhuis W. Joost , Croockewit Alexandra J. , de Wilt Johannes H. W. , van Rossum Michelle M. , Blokx Willeke A. M. , Jacobs Joannes F. M. , Duiveman-de Boer Tjitske , Schuurhuis Danita H. , Mus Roel , Thielemans Kris , de Vries I. Jolanda M. , Figdor Carl G. , Punt Cornelis J. A. , Adema Gosse J.
Published: April 2023

PDF file, 96K, Detection of tumor-specific T cells in SKIL cultures does not require challenge with defined epitopes. Tetramer analysis of SKILs cultured from biopsies of DTH reactions to DCs pulsed with tumor peptides (upper plots) or DCs electroporated with mRNA encoding tumor proteins (lower plots) of patients II-E-09 (A), II-E-03 (B), and II-E-10 (C). This figure shows that sampling DTH biopsy cultures with tetramers yields similar results when the patient is challenged with intradermal injections with DC pulsed with defined epitopes or DC electroporated with mRNA encoding the full tumor antigen.
Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Authors: Frantzi Maria , van Kessel Kim E. , Zwarthoff Ellen C. , Marquez Mirari , Rava Marta , Malats Núria , Merseburger Axel S. , Katafigiotis Ioannis , Stravodimos Konstantinos , Mullen William , Zoidakis Jerome , Makridakis Manousos , Pejchinovski Martin , Critselis Elena , Lichtinghagen Ralph , Brand Korbinian , Dakna Mohammed , Roubelakis Maria G. , Theodorescu Dan , Vlahou Antonia , Mischak Harald , Anagnou Nicholas P.
Published: April 2023

Supplementary Table S8. Correlation analysis of the 116 peptide biomarkers with disease stage and grade and performance of peptide classifiers in detecting NMIBC and MIBC.
Figure S3 from Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Authors: Merino Diana M. , Shlien Adam , Villani Anita , Pienkowska Malgorzata , Mack Stephen , Ramaswamy Vijay , Shih David , Tatevossian Ruth , Novokmet Ana , Choufani Sanaa , Dvir Rina , Ben-Arush Myran , Harris Brent T. , Hwang Eugene I. , Lulla Rishi , Pfister Stefan M. , Achatz Maria Isabel , Jabado Nada , Finlay Jonathan L. , Weksberg Rosanna , Bouffet Eric , Hawkins Cynthia , Taylor Michael D. , Tabori Uri , Ellison David W. , Gilbertson Richard J. , Malkin David
Published: April 2023

Figure S3. Ploidy values obtained from allele-specific copy number analysis are depicted. Scatter plot of CPCs (red), CPPs (yellow) and aCPPs (light blue) showing two distinct groups in CPCs: hypodiploid CPCs (dark blue), and hyperdiploid CPCs (green) exhibiting significant differences (Mann-Whitney test p=1.00x10-4).
Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Authors: Frantzi Maria , van Kessel Kim E. , Zwarthoff Ellen C. , Marquez Mirari , Rava Marta , Malats Núria , Merseburger Axel S. , Katafigiotis Ioannis , Stravodimos Konstantinos , Mullen William , Zoidakis Jerome , Makridakis Manousos , Pejchinovski Martin , Critselis Elena , Lichtinghagen Ralph , Brand Korbinian , Dakna Mohammed , Roubelakis Maria G. , Theodorescu Dan , Vlahou Antonia , Mischak Harald , Anagnou Nicholas P.
Published: April 2023

Supplementary Table S5. List of all peptides that were included in the peptide biomarker panels for detecting primary and recurrent UBC. For primary UBC, 116 peptide biomarkers were employed and optimized in an SVM-based classifier, using the discovery set of 451 urine samples (n=341 primary UBC cases, n=110 urological controls). For recurrent UBC, 106 peptide biomarkers were included and subsequently optimized in 109 recurrent UBC cases confirmed after cystoscopy and 316 negative for recurrence controls. The characteristics of all the sequenced peptide biomarkers are given, molecular mass (in Da), amino acid sequence, precursor protein, p values, mean amplitude and frequency of the peptides.
Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Authors: Frantzi Maria , van Kessel Kim E. , Zwarthoff Ellen C. , Marquez Mirari , Rava Marta , Malats Núria , Merseburger Axel S. , Katafigiotis Ioannis , Stravodimos Konstantinos , Mullen William , Zoidakis Jerome , Makridakis Manousos , Pejchinovski Martin , Critselis Elena , Lichtinghagen Ralph , Brand Korbinian , Dakna Mohammed , Roubelakis Maria G. , Theodorescu Dan , Vlahou Antonia , Mischak Harald , Anagnou Nicholas P.
Published: April 2023

Supplementary Table S4. Table summarizing the significant biomarkers that were revealed after statistical analysis between recurrent UBC cases (n=109) and negative for recurrence controls (n=316), using Wilcoxon test. The significant biomarkers were subsequently compared for their trend of regulation among the different centers, as shown in the second table sheet.
Figure S1 from Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Authors: Merino Diana M. , Shlien Adam , Villani Anita , Pienkowska Malgorzata , Mack Stephen , Ramaswamy Vijay , Shih David , Tatevossian Ruth , Novokmet Ana , Choufani Sanaa , Dvir Rina , Ben-Arush Myran , Harris Brent T. , Hwang Eugene I. , Lulla Rishi , Pfister Stefan M. , Achatz Maria Isabel , Jabado Nada , Finlay Jonathan L. , Weksberg Rosanna , Bouffet Eric , Hawkins Cynthia , Taylor Michael D. , Tabori Uri , Ellison David W. , Gilbertson Richard J. , Malkin David
Published: April 2023

Figure S1. Sample flow-chart describing the number of biological samples and clinical data obtained through an international multi-institutional effort and the distribution of samples in each microarray
Appendix from Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Authors: Merino Diana M. , Shlien Adam , Villani Anita , Pienkowska Malgorzata , Mack Stephen , Ramaswamy Vijay , Shih David , Tatevossian Ruth , Novokmet Ana , Choufani Sanaa , Dvir Rina , Ben-Arush Myran , Harris Brent T. , Hwang Eugene I. , Lulla Rishi , Pfister Stefan M. , Achatz Maria Isabel , Jabado Nada , Finlay Jonathan L. , Weksberg Rosanna , Bouffet Eric , Hawkins Cynthia , Taylor Michael D. , Tabori Uri , Ellison David W. , Gilbertson Richard J. , Malkin David
Published: April 2023

Appendix
Supplemental Figure S1 to S14 Legends from Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation
Authors: Palanichamy Kamalakannan , Thirumoorthy Krishnan , Kanji Suman , Gordon Nicolaus , Singh Rajbir , Jacob John R. , Sebastian Nikhil , Litzenberg Kevin T. , Patel Disha , Bassett Emily , Ramasubramanian Brinda , Lautenschlaeger Tim , Fischer Steven M. , Ray-Chaudhury Abhik , Chakravarti Arnab
Published: April 2023

Supporting Figure S1 to S14 Legends
Supplemental Figure Legends from Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer
Authors: Schneider Marc A. , Granzow Martin , Warth Arne , Schnabel Philipp A. , Thomas Michael , Herth Felix J.F. , Dienemann Hendrik , Muley Thomas , Meister Michael
Published: April 2023

Supplemental Figure Legends. Figure legends for the supplemental figures.
Figure S1 from Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer
Authors: Schneider Marc A. , Granzow Martin , Warth Arne , Schnabel Philipp A. , Thomas Michael , Herth Felix J.F. , Dienemann Hendrik , Muley Thomas , Meister Michael
Published: April 2023

Figure S1. Survival of females with high PAEP expression.
Supplemental Figure 3 from MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
Authors: Angell Trevor E. , Lechner Melissa G. , Jang Julie K. , LoPresti Jonathan S. , Epstein Alan L.
Published: April 2023

Supplemental Figure 3. Effect of specific BRAFV600E or radiation on PTC cell line MHC class I expression. (A) The effect of in vitro treatment of PTC cell lines with BRAFV600E-specific tyrosine kinase inhibitors vemurafenib or PLX 4720 on HLA-ABC expression as measured by flow cytometry. (B) The effect of 30 or 60Gy radiation treatment on HLA-ABC expression by PTC cell lines as measured by flow cytometry with data shown as mean +SEM. Representative flow cytometry histograms for HLA-ABC expression are shown to the right. (C) T cell activation measured as the CD25+ fraction of CD3+ T cells or (D) IL-2 production in PBL-PTC cell line co-cultures after PTC tumor cells were pre-treated with radiation. For C and D, data shown are mean (n=4) +SEM, with statistically significant difference from vehicle-treated PTC indicated by *** p<0.001.
Supplemental Figure 1 from MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
Authors: Angell Trevor E. , Lechner Melissa G. , Jang Julie K. , LoPresti Jonathan S. , Epstein Alan L.
Published: April 2023

Supplemental Figure 1. Immunohistochemical staining for tumor-infiltrating leukocyte populations in papillary thyroid cancer specimens and control tissues. Examples of positive and negative staining are shown (original magnification 400x), with black arrows demonstrating instances of positively stained target cells for each stain.
Data Supplement from Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression
Authors: Wang Ren-Tao , Xu Meng , Xu Cheng-Xiong , Song Zhi-Gang , Jin Hua
Published: April 2023

Supplementary Figure 1. miR-216a negatively regulates non-small cell lung cancer cell growth. Supplementary Figure 2. miR-216a induces apoptosis in vitro and in vivo. Supplementary Figure 3. miR-216a inhibits EMT in non-small cell lung cancer cell. Supplementary Figure 4. Anti-Argonaute 2 RIP-Chip assay shows that overexpression of miR-216a increased Ago2 complex and ZEB1/eIF4B mRNA interaction. Supplementary Figure 5. Correlation of ZEB1/eIF4B expression and miR-216a expression or non-small cell lung cancer (NSCLC) patients' survival. Supplementary Figure 6. Effects of miR-216a on putative target genes expression in A549 and HepG2 cells. Supplementary Figure 7. Expression of miR-216a, ZEB1 and eIF4B. A549 cells were tranfected with indicated plasmid.
Supplementary Methods and Legend from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
Authors: Pokorny Jenny L. , Calligaris David , Gupta Shiv K. , Iyekegbe Dennis O. , Mueller Dustin , Bakken Katrina K. , Carlson Brett L. , Schroeder Mark A. , Evans Debra L. , Lou Zhenkun , Decker Paul A. , Eckel-Passow Jeanette E. , Pucci Vincenzo , Ma Bennett , Shumway Stuart D. , Elmquist William F. , Agar Nathalie Y.R. , Sarkaria Jann N.
Published: April 2023

Supplementary Methods and Legend
Supplementary Figure S5 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
Authors: Pokorny Jenny L. , Calligaris David , Gupta Shiv K. , Iyekegbe Dennis O. , Mueller Dustin , Bakken Katrina K. , Carlson Brett L. , Schroeder Mark A. , Evans Debra L. , Lou Zhenkun , Decker Paul A. , Eckel-Passow Jeanette E. , Pucci Vincenzo , Ma Bennett , Shumway Stuart D. , Elmquist William F. , Agar Nathalie Y.R. , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S5. MALDI-TOF MS analyses of MK-1775 (m/z 501.2)in brain and flank GBM22 tumor samples after treatment with placebo or MK-1775
Supplementary Table S3 from The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Authors: Wen Chi-Pang , Zhang Fanmao , Liang Dong , Wen Christopher , Gu Jian , Skinner Heath , Chow Wong-Ho , Ye Yuanqing , Pu Xia , Hildebrandt Michelle A.T. , Huang Maosheng , Chen Chien-Hua , Hsiung Chao Agnes , Tsai Min Kuang , Tsao Chwen Keng , Lippman Scott M. , Wu Xifeng
Published: April 2023

Supplementary Table S3. Metabolites with significant trend of expression comparing normal controls and lung cancer stages
Supplementary Figure S5 from The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Authors: Wen Chi-Pang , Zhang Fanmao , Liang Dong , Wen Christopher , Gu Jian , Skinner Heath , Chow Wong-Ho , Ye Yuanqing , Pu Xia , Hildebrandt Michelle A.T. , Huang Maosheng , Chen Chien-Hua , Hsiung Chao Agnes , Tsai Min Kuang , Tsao Chwen Keng , Lippman Scott M. , Wu Xifeng
Published: April 2023

Supplementary Figure S5. Levels of the two individual metabolites of interest measured with LC/MS-MS in a case-control study in three phases
Supplemental Figure S3 from On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
Authors: Gehrke Iris , Bouchard Eric D.J. , Beiggi Sara , Poeppl Armando G. , Johnston James B. , Gibson Spencer B. , Banerji Versha
Published: April 2023

Figure S3: Cells were treated for one, two or three days with FK866 at 1 nM, 10 nM and 50 nM. A) AMPK was phosphorylated at all concentrations at day 1, but only at 1 nM after three days incubation with FK866. B) mTOR was phosphorylated at 1 nM and 10 nM FK866 at day 2. C) Erk1/2 was phosphorylated at 1 nM FK866 at day 2. Vinculin served as loading control. Ctrl: vehicle control
Supplementary Table 2 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Authors: Holkova Beata , Supko Jeffrey G. , Ames Matthew M. , Reid Joel M. , Shapiro Geoffrey I. , Perkins Edward Brent , Ramakrishnan Viswanathan , Tombes Mary Beth , Honeycutt Connie , McGovern Renee M. , Kmieciak Maciej , Shrader Ellen , Wellons Martha D. , Sankala Heidi , Doyle Austin , Wright John , Roberts John D. , Grant Steven
Published: April 2023

PDF file - 42K, Alvocidib pharmacokinetic parameters.
Supplementary Table 1 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Authors: Holkova Beata , Supko Jeffrey G. , Ames Matthew M. , Reid Joel M. , Shapiro Geoffrey I. , Perkins Edward Brent , Ramakrishnan Viswanathan , Tombes Mary Beth , Honeycutt Connie , McGovern Renee M. , Kmieciak Maciej , Shrader Ellen , Wellons Martha D. , Sankala Heidi , Doyle Austin , Wright John , Roberts John D. , Grant Steven
Published: April 2023

PDF file - 39K, Response by schedule and diagnosis.
Supplementary Figure Legends from Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
Authors: Carlino Matteo S. , Fung Carina , Shahheydari Hamideh , Todd Jason R. , Boyd Suzanah C. , Irvine Mal , Nagrial Adnan M. , Scolyer Richard A. , Kefford Richard F. , Long Georgina V. , Rizos Helen
Published: April 2023

Supplementary Figure Legends
Supplementary Data from First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Authors: Basu Bristi , Dean Emma , Puglisi Martina , Greystoke Alastair , Ong Michael , Burke Wendy , Cavallin Maria , Bigley Graham , Womack Christopher , Harrington Elizabeth A. , Green Stephen , Oelmann Elisabeth , de Bono Johann S. , Ranson Malcolm , Banerji Udai
Published: April 2023

Supplementary Data - materials and methods
supplementary tables 1-5 from Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Authors: Weed Donald T. , Vella Jennifer L. , Reis Isildinha M. , De la fuente Adriana C. , Gomez Carmen , Sargi Zoukaa , Nazarian Ronen , Califano Joseph , Borrello Ivan , Serafini Paolo
Published: April 2023

supplementary tables 1-5. Suppl.table 1: Retrospective case-control study: Patient characteristics: overall and by recurrence status; Suppl.table 2: Prospective Tadalafil study: Patients and tumor characteristics according to study arms; Suppl.table 3: Adverse Events (AE)by study arm; Suppl.table 4: Logistic regression analyses on the retrospective case-control study; Suppl.table 5: Effect of Tadalafil on blood CD4/CD8 ratio
Supplementary methods from Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Authors: Weed Donald T. , Vella Jennifer L. , Reis Isildinha M. , De la fuente Adriana C. , Gomez Carmen , Sargi Zoukaa , Nazarian Ronen , Califano Joseph , Borrello Ivan , Serafini Paolo
Published: April 2023

Supplementary methods. Description of the patients for the retrospective and the prospective study, list of inclusion and exclusion criteria, and detailed protocol for immunofluorescence analysis.
Figure S1 from Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers
Authors: Lombardi Anne J. , Hoskins Elizabeth E. , Foglesong Grant D. , Wikenheiser-Brokamp Kathryn A. , Wiesmüller Lisa , Hanenberg Helmut , Andreassen Paul R. , Jacobs Allison J. , Olson Susan B. , Keeble Winifred W. , Hays Laura E. , Wells Susanne I.
Published: April 2023

Figure S1. Squamous cell carcinoma formation and survival in Fancc-/- and wild type mice
Supplementary Table 1 from Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas
Authors: Gonzalez-Aguilar Alberto , Idbaih Ahmed , Boisselier Blandine , Habbita Naïma , Rossetto Marta , Laurenge Alice , Bruno Aurélie , Jouvet Anne , Polivka Marc , Adam Clovis , Figarella-Branger Dominique , Miquel Catherine , Vital Anne , Ghesquières Hervé , Gressin Rémy , Delwail Vincent , Taillandier Luc , Chinot Olivier , Soubeyran Pierre , Gyan Emmanuel , Choquet Sylvain , Houillier Caroline , Soussain Carole , Tanguy Marie-Laure , Marie Yannick , Mokhtari Karima , Hoang-Xuan Khê
Published: April 2023

PDF file, 55K, Table S1: Recurrent chromosome region imbalances found in more than 20% of PCNSLs investigated by high resolution genomic arrays.
Supplementary Figures 1 - 7 from A Surprising Cross-Species Conservation in the Genomic Landscape of Mouse and Human Oral Cancer Identifies a Transcriptional Signature Predicting Metastatic Disease
Authors: Onken Michael D. , Winkler Ashley E. , Kanchi Krishna-Latha , Chalivendra Varun , Law Jonathan H. , Rickert Charles G. , Kallogjeri Dorina , Judd Nancy P. , Dunn Gavin P. , Piccirillo Jay F. , Lewis James S. , Mardis Elaine R. , Uppaluri Ravindra
Published: April 2023

PDF file - 486KB, Figure S1 (A) Average statistics for depth of coverage at 20X, 30X and 40X of all MOC lines. Robust reads were obtained in all samples with a range of 97-98 percent for 20X, 93-95 percent for 30X and 88-92 percent for 40X. (B) Putative SNVs, nsSNVs (Table S1 and S2) and Indels (Table S4) of all MOC lines. Figure S2 Oncoprints from cBio of AKAP9, MED12L, THSD7A, MUC5B, MYH6, LAMA1, LRP2, and 3 RAS (Table S6) genes representing other candidate tumor promoters as compared to the 3 RAS genes. Note that for AKAPs and MED components, we found 9 AKAP family member mutations in 20.4 percent of tumors, with AKAP9 changes in 7 percent (Fig. 1D). Six components of the mediator complex were mutated in 14.7% of cases, with MED12L changes in 5% (Fig. 1E). Figure S3 Number of nsSNV's per node negative (N0) and node positive (N+) tumor in (A) all TCGA OSCC (note that patient TCGA-D6-6516 (N0) with 1463 mutations is not included in this graph) and (B) TCGA OSCC patients who had smoking history reported. There was no significant difference in the average number of mutations between N0 (3272 nsSNVs) and N+ (3097 nsSNVs) patients regardless of smoking status (Tables S8, S9). This analysis showed 17 genes commonly mutated in mouse indolent and human N0 tumors and 55 common genes mutated in mouse aggressive and human N+ tumors (Supplementary Table S10). However, none of these common genes were mutated at high frequency in the human N0 or N+ datasets (Supplementary Table S11 and 12). Finally, comparing N0 and N+ tumors from human TCGA data also showed that specific mutations occur infrequently in both the metastatic and non-metastatic tumors (data not shown). Figure S4 SAM plotsheet of MOC line microarray data with estimated miss rates for delta=4.68 Figure S5 (A) GSEA data of OCAMP-A on UW/FHCRC data with (B) first condensation of enriched genes. (C) GSEA data of OCAMP-A on MDA data with (D) first condensation of enriched genes. (E) GSEA data of OCAMP-A on TCGA data with (F) first condensation of enriched genes. Figure S6 (A) Disease specific survival (DSS) after weighted voting classification of OCAMP-B signature on the MD Anderson dataset shows worse outcome for those with aggressive classification (p=0.028). Figure S7 (A) Disease specific survival (DSS) and (B) overall survival (OS) after weighted voting classification of OCAMP-B signature on the UW/FHCRC dataset shows worse outcome for those with aggressive classification (p<0.01).
Data Supplement from An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer
Authors: Noguchi Satoshi , Saito Akira , Horie Masafumi , Mikami Yu , Suzuki Hiroshi I. , Morishita Yasuyuki , Ohshima Mitsuhiro , Abiko Yoshimitsu , Mattsson Johanna Sofia Margareta , König Helena , Lohr Miriam , Edlund Karolina , Botling Johan , Micke Patrick , Nagase Takahide
Published: April 2023

Supplementary Figure S4. TAZ regulates ErbB ligand expression.
Supplementary Table 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Authors: Oberthuer André , Juraeva Dilafruz , Hero Barbara , Volland Ruth , Sterz Carolina , Schmidt Rene , Faldum Andreas , Kahlert Yvonne , Engesser Anne , Asgharzadeh Shahab , Seeger Robert , Ohira Miki , Nakagawara Akira , Scaruffi Paola , Tonini Gian Paolo , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun , Vandesompele Jo , Speleman Frank , Noguera Rosa , Piqueras Marta , Bénard Jean , Valent Alexander , Avigad Smadar , Yaniv Isaac , Grundy Richard G. , Ortmann Monika , Shao Chunxuan , Schwab Manfred , Eils Roland , Simon Thorsten , Theissen Jessica , Berthold Frank , Westermann Frank , Brors Benedikt , Fischer Matthias
Published: April 2023

Supplementary Table 2. External performance validation of the top five classifiers. This supplementary table comprises the external performance metrics of the top five classifiers. Indicated are the values for classification accuracy, sensitivity , specificity and Matthew's correlation coefficient (MCC) in the prediction of 325 patients of the test set who fulfilled the criteria for classifier training (Favorable, n=187; Unfavorable, n=138).
Supplementary Figure 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Authors: Oberthuer André , Juraeva Dilafruz , Hero Barbara , Volland Ruth , Sterz Carolina , Schmidt Rene , Faldum Andreas , Kahlert Yvonne , Engesser Anne , Asgharzadeh Shahab , Seeger Robert , Ohira Miki , Nakagawara Akira , Scaruffi Paola , Tonini Gian Paolo , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun , Vandesompele Jo , Speleman Frank , Noguera Rosa , Piqueras Marta , Bénard Jean , Valent Alexander , Avigad Smadar , Yaniv Isaac , Grundy Richard G. , Ortmann Monika , Shao Chunxuan , Schwab Manfred , Eils Roland , Simon Thorsten , Theissen Jessica , Berthold Frank , Westermann Frank , Brors Benedikt , Fischer Matthias
Published: April 2023

Supplementary Figure 1. Highlights the EFS and OS for the cohort of neuroblastoma patients with MYCN-amplified disease (n=114, Fig 1a) and for th subcohort of patients >18 months of age with stage 4, MYCN non-amplified disease (n=102, fig. 1b). F, favorable; UF, unfavorable.
Supplementary Figure 1 from Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity
Authors: Khiati Salim , Dalla Rosa Ilaria , Sourbier Carole , Ma Xuefei , Rao V. Ashutosh , Neckers Leonard M. , Zhang Hongliang , Pommier Yves
Published: April 2023

PDF file - 86KB, A, Mitochondrial cross-section area bins after saline or DOX injection (top and bottom panels, respectively). A total of 250 mitochondria from each condition were analyzed from 5 electrons micrographs taken at 3000 X magnifications in 4 to 6 different sections. Two animals were used for each condition. B, Electron microscopy quantification of mitochondria numbers in heart right ventricle after saline or DOX injections. Five electron micrographs taken at 3000 X magnification in 4 to 6 different sections. Two representative animals were used for each condition. Between 1500 to 2700 mitochondria were counted.
Supplementary Table 3 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
Authors: Wheeler Heather E. , Gamazon Eric R. , Wing Claudia , Njiaju Uchenna O. , Njoku Chidiamara , Baldwin Robert Michael , Owzar Kouros , Jiang Chen , Watson Dorothy , Shterev Ivo , Kubo Michiaki , Zembutsu Hitoshi , Winer Eric P. , Hudis Clifford A. , Shulman Lawrence N. , Nakamura Yusuke , Ratain Mark J. , Kroetz Deanna L. , Cox Nancy J. , Dolan Mary Eileen
Published: April 2023

PDF file - 68K, Expression and eQTL status of the patient/LCL overlap genes and SNPs.
Legends to Supplementaries from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Authors: Oberthuer André , Juraeva Dilafruz , Hero Barbara , Volland Ruth , Sterz Carolina , Schmidt Rene , Faldum Andreas , Kahlert Yvonne , Engesser Anne , Asgharzadeh Shahab , Seeger Robert , Ohira Miki , Nakagawara Akira , Scaruffi Paola , Tonini Gian Paolo , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun , Vandesompele Jo , Speleman Frank , Noguera Rosa , Piqueras Marta , Bénard Jean , Valent Alexander , Avigad Smadar , Yaniv Isaac , Grundy Richard G. , Ortmann Monika , Shao Chunxuan , Schwab Manfred , Eils Roland , Simon Thorsten , Theissen Jessica , Berthold Frank , Westermann Frank , Brors Benedikt , Fischer Matthias
Published: April 2023

Legends to Supplementaries. This documents comprises the legends to the supplementary figures and tables
Supplementary Figure 1 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
Authors: Wheeler Heather E. , Gamazon Eric R. , Wing Claudia , Njiaju Uchenna O. , Njoku Chidiamara , Baldwin Robert Michael , Owzar Kouros , Jiang Chen , Watson Dorothy , Shterev Ivo , Kubo Michiaki , Zembutsu Hitoshi , Winer Eric P. , Hudis Clifford A. , Shulman Lawrence N. , Nakamura Yusuke , Ratain Mark J. , Kroetz Deanna L. , Cox Nancy J. , Dolan Mary Eileen
Published: April 2023

PDF file - 409K, SNP call plots from the CALGB 40101 patient genotyping on the Illumina 610-Quad platform for the patient/LCL overlap SNPs in genes. R is the combined SNP intensity and theta is the allelic intensity ratio.
Supplementary Figure 4 from MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
Authors: Chang Wendy , Brohl Andrew S. , Patidar Rajesh , Sindiri Sivasish , Shern Jack F. , Wei Jun S. , Song Young K. , Yohe Marielle E. , Gryder Berkley , Zhang Shile , Calzone Kathleen A. , Shivaprasad Nityashree , Wen Xinyu , Badgett Thomas C. , Miettinen Markku , Hartman Kip R. , League-Pascual James C. , Trahair Toby N. , Widemann Brigitte C. , Merchant Melinda S. , Kaplan Rosandra N. , Lin Jimmy C. , Khan Javed
Published: April 2023

Imaging from two clinical vignettes highlighting the importance of sequencing at diagnosis and relapse. A. An epithelioid inflammatory myofibroblastic sarcoma (Patient NCI0244) positive for a RANBP2-ALK fusion leading to activation of ALK was treated with targeted monotherapy. PET scans are shown in the top row. At initial diagnosis, abdominal tumors were located in the left upper quadrant with extensive FDG-avid peritoneal lesions. Clinical response after 8 months of targeted therapy with crizotinib was noted. First relapse with development of a recurrent nodule noted in between the right kidney and duodenum with pulmonary and hepatic metastases was observed after 14 months of crizotinib therapy. A secondary clinical response after treatment with ceritinib was obtained after 1 month of therapy, but was not maintained. The primary tumor sample derived cell line, labeled Tumor.1, did not contain an ALK I1171T mutation. Sanger validation confirmed the presence of an ALK p.I1171T mutation after targeted therapy with crizotinib and ceritinib. The patient's tumor samples all contained a RANBP2-ALK fusion, which was not present in the germline. B. A GNAQ Q209L mutation-positive melanoma (Patient NCI0155), treated with trametinib. The melanoma originated from the left frontotemporal scalp and left orbit, and was metastatic to regional lymph nodes, dura mater, liver, bone and lung as shown on CT (first column, first row) with PET avidity in metastases (first column, second row). WES and WTS of her tumor revealed a GNAQ Q209L mutation. The patient was treated with trametinib and had an initial mixed response, with loss of PET avidity of several liver metastases (second column, second row). However, progressive disease of the primary tumor was noted 5 months after initiating therapy, and PET/CT scans showed increased size of the primary tumor in the scalp (third column, first row)
Supplementary Figure 2 from MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
Authors: Chang Wendy , Brohl Andrew S. , Patidar Rajesh , Sindiri Sivasish , Shern Jack F. , Wei Jun S. , Song Young K. , Yohe Marielle E. , Gryder Berkley , Zhang Shile , Calzone Kathleen A. , Shivaprasad Nityashree , Wen Xinyu , Badgett Thomas C. , Miettinen Markku , Hartman Kip R. , League-Pascual James C. , Trahair Toby N. , Widemann Brigitte C. , Merchant Melinda S. , Kaplan Rosandra N. , Lin Jimmy C. , Khan Javed
Published: April 2023

An adrenocortical carcinoma in Patient NCI0226 with a de-novo germline TP53 mutation. Germline DNA samples from brother and parents were not noted to have the mutation. The mutation was a novel two base substitution at codon c.358_359delCGinsAA, leading to an amino acid change, A159K. The mutation was heterozygous in the germline, and homozygous in tumor exome and transcriptome due to loss of heterozygosity of the wild-type allele.
Supplementary Table 4 from Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer
Authors: Ciarloni Laura , Ehrensberger Sahar Hosseinian , Imaizumi Natsuko , Monnier-Benoit Sylvain , Nichita Cristina , Myung Seung-Jae , Kim Joo Sung , Song Si Young , Kim Tae Il , van der Weg Boudewijn , Meier Rémy , Borovicka Jan , Beglinger Christoph , Vallet Cédric , Maerten Philippe , Rüegg Curzio , Dorta Gian
Published: April 2023

Positive rate of the predictive MGMC and MGMC-P algorithms applied to non per-protocol cases. This table provides the positive rate of the predictive MGMC and MGMC-P algorithms applied to non per-protocol cases
Supplementary Table 1 from Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer
Authors: Ciarloni Laura , Ehrensberger Sahar Hosseinian , Imaizumi Natsuko , Monnier-Benoit Sylvain , Nichita Cristina , Myung Seung-Jae , Kim Joo Sung , Song Si Young , Kim Tae Il , van der Weg Boudewijn , Meier Rémy , Borovicka Jan , Beglinger Christoph , Vallet Cédric , Maerten Philippe , Rüegg Curzio , Dorta Gian
Published: April 2023

The 29-gene panel for colorectal cancer and large adenoma detection. Gene expression profiles obtained from the training set were explored by univariate analysis to compare the behavior of the 29 genes across the control (CON), the CRC and the LAP groups. Twelve genes were significantly differentially expressed in CRC and LAP compared to controls (p-value<0.05) by Wilcoxon rank test, applied to normalized gene expressions. Relative abundance of a gene transcript is represented by the fold change (FC), defined as ã€-FCã€-_gene ã€-=2ã€-^â^†â^†Cp , where â^†â^†Cp=mean(ã€-â^†Cpã€-_Disease )-mean(ã€-â^†Cpã€-_Control ).
Supplementary Figure 3 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Authors: Sarker Debashis , Ang Joo Ern , Baird Richard , Kristeleit Rebecca , Shah Krunal , Moreno Victor , Clarke Paul A. , Raynaud Florence I. , Levy Gallia , Ware Joseph A. , Mazina Kathryn , Lin Ray , Wu Jenny , Fredrickson Jill , Spoerke Jill M. , Lackner Mark R. , Yan Yibing , Friedman Lori S. , Kaye Stan B. , Derynck Mika K. , Workman Paul , de Bono Johann S.
Published: April 2023

Supplementary Figure 3. Details of a 49 year old patient with platinum-refractory metastatic ovarian cancer and 5 previous lines of chemotherapy treated with oral pictilisib at 100mg once-daily on days 1-21 every 28 days.
CCR Translation for This Article from Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer
Authors: Julien Sylvia , Merino-Trigo Ana , Lacroix Ludovic , Pocard Marc , Goéré Diane , Mariani Pascale , Landron Sophie , Bigot Ludovic , Nemati Fariba , Dartigues Peggy , Weiswald Louis-Bastien , Lantuas Denis , Morgand Loïc , Pham Emmanuel , Gonin Patrick , Dangles-Marie Virginie , Job Bastien , Dessen Philippe , Bruno Alain , Pierré Alain , De Thé Hugues , Soliman Hany , Nunes Manoel , Lardier Guillaume , Calvet Loreley , Demers Brigitte , Prévost Grégoire , Vrignaud Patricia , Roman-Roman Sergio , Duchamp Olivier , Berthet Cyril
Published: April 2023

CCR Translation for This Article from Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer
Data Supplement from Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
Authors: Zhang Zhe , Wang Jiping , Ji Dongmei , Wang Chenchen , Liu Rujiao , Wu Zheng , Liu Lian , Zhu Dan , Chang Jinjia , Geng Ruixuan , Xiong Lei , Fang Qiangyi , Li Jin
Published: April 2023

Supplementary Figure 2. Knockdown of Each Gene Was Confirmed by PCR or Western Blot Analysis
Data Supplement from Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
Authors: Zhang Zhe , Wang Jiping , Ji Dongmei , Wang Chenchen , Liu Rujiao , Wu Zheng , Liu Lian , Zhu Dan , Chang Jinjia , Geng Ruixuan , Xiong Lei , Fang Qiangyi , Li Jin
Published: April 2023

Supplementary Table 1. Top 10 gene targets from shRNA screen that increase lapatinib sensitivity. Supplementary Table 2. Summary of RTK-mediated rescue results from lapatinib in HER2-addicted cancer cell lines. Supplementary Table 3. Clinicopathologic characteristics and immunohistochemical variables of patients.
Supplementary Figures 1 - 6 from Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer
Authors: Tiriveedhi Venkataswarup , Tucker Natalia , Herndon John , Li Lijin , Sturmoski Mark , Ellis Matthew , Ma Cynthia , Naughton Michael , Lockhart A. Craig , Gao Feng , Fleming Timothy , Goedegebuure Peter , Mohanakumar Thalachallour , Gillanders William E.
Published: April 2023

Supplementary Figure 1: Expression of MAM-A and HLA-A2 in breast cancer cell lines. Supplementary Figure 2: MAM-A DNA vaccination increases breast cancer-induced TNF-α production by MAM-A-specific CD8 T cells. Supplementary Figure 3: MAM-A DNA vaccination increases NKG2D expression in MAM-A-specific CD8 T cells. Supplementary Figure 4: MAM-A DNA vaccination increases DAP10 adapter protein expression in MAM-A-specific CD8 T cells. Supplementary Figure 5: MAM-A DNA vaccination increases perforin expression in MAM-A-specific CD8 T cells. Supplementary Figure 6: Therapy received by the patients (screen failed and vaccinated).
Supplementary Table 3 from Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer
Authors: Burdelski Christoph , Reiswich Viktor , Hube-Magg Claudia , Kluth Martina , Minner Sarah , Koop Christina , Graefen Markus , Heinzer Hans , Tsourlakis Maria Christina , Wittmer Corinna , Huland Hartwig , Simon Ronald , Schlomm Thorsten , Sauter Guido , Steurer Stefan
Published: April 2023

Supplementary Table 3. Clinico-pathological association of p62 immunostaining in ERG fusion positive cancers